Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Pucotenlimab for Advanced Penile Squamous Cell Carcinoma
NCT07518979Phase 2Recruiting
- Start
- Jul 2026
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in penile squamous cell carcinoma (PSCC). Started Jul 2026; status: recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT07518979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518979.